58 articles tagged with #congress. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Senator Elizabeth Warren is calling for anti-corruption provisions to be included in crypto legislation currently moving through Congress. Warren referenced the SEC's recent settlement with Tron founder Justin Sun as justification for addressing corruption issues in the cryptocurrency space.
The crypto market structure CLARITY Act faces significant delays due to banking sector opposition to stablecoin reward provisions, with passage by 2026 now in doubt. Despite White House compromise attempts, banks remain concerned about deposit flight and continue to oppose the legislation, while time constraints from upcoming midterm elections further complicate prospects.
The U.S. Senate has advanced a housing bill that includes a ban on Central Bank Digital Currencies (CBDCs), receiving strong bipartisan support and backing from the White House. The significant bipartisan vote suggests the legislation has momentum to pass additional procedural hurdles in Congress.
The article presents Questions for the Record submitted following Sam Altman's testimony before the U.S. Senate Judiciary Subcommittee on Privacy, Technology, and Law. This represents formal follow-up questions from senators seeking additional details on AI governance, regulation, and policy matters discussed during the hearing.
Republican Rep. French Hill is urging the Senate to address the stablecoin yield controversy by taking up the House's cryptocurrency legislation. This appears to be part of ongoing efforts to resolve regulatory disputes around stablecoin regulations.
The SEC's Office of the Advocate for Small Business Capital Formation published its 2025 staff report analyzing capital-raising dynamics and delivered it to Congress. The report serves as a comprehensive data resource examining current trends and challenges in capital formation for small businesses.
The article discusses how Congressional actions have complicated Trump's promise to lower drug prices, with Mark Cuban referencing pricing transparency issues. Limited content suggests focus on healthcare policy and pricing mechanisms.
